A Panel of Circulating Non-Coding RNAs in the Diagnosis and Monitoring of Therapy in Egyptian Patients with Breast Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Feb 25

PMID 36831100

Authors

Nadine Wehida

Wafaa Abdel-Rehim

Hazem El Mansy

Ahmed Karmouty

Maher A Kamel

Affiliations

Soon will be listed here.

Abstract

Non-coding RNAs (ncRNAs) have recently been identified to have a pivotal role in many diseases, including breast cancer (BC). This study aims to investigate the relative quantification of long non-coding RNA (lncRNA) H19, microRNA (miR) 675-5p, 675-3p, and miR-let 7 in breast cancer patients. The study was performed on three groups: Group 1: 30 non-intervened BC female patients about to undergo breast surgery; group 2: 30 postoperative female BC patients about to receive adjuvant anthracycline chemotherapy; and group 3: 30 apparently healthy female volunteers as the control group. Plasma samples were drawn before and after the intervention in groups 1 and 2, with a single sample drawn from group 3. The relative quantification levels were compared with healthy control subjects and were related with the clinicopathological statuses of these patients. There was a statistically significant increase in H19, miR-675-5p, miR-675-3p, and miR-let 7 in the non-intervened BC patients when compared to the control group. Surgery resulted in a significant reduction in all four ncRNAs under investigation. Chemotherapy brought about a significant increase in the level of miR-let 7, with no significant effect on the remaining parameters measured. The assay discriminated normal from BC where a receiver operating characteristic for the area under the curve (ROC) of miR-675-3p showed the maximal AUC of 1.000. The diagnostic sensitivity and specificity were also 100% when CA 15-3 and H19 were combined. : The results strongly indicate that the panel of ncRNAs in this study can all potentially act as novel biomarkers whether alone or combined in the diagnosis of BC.

References

Qi P, Du X . The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2012; 26(2):155-65. DOI: 10.1038/modpathol.2012.160. View

Zhong G, Wang K, Li J, Xiao S, Wei W, Liu J . Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis. Onco Targets Ther. 2020; 13:2563-2571. PMC: 7109356. DOI: 10.2147/OTT.S243601. View

Heneghan H, Miller N, Lowery A, Sweeney K, Newell J, Kerin M . Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3):499-505. DOI: 10.1097/SLA.0b013e3181cc939f. View

Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Volkel P . Enhancement of Breast Cancer Cell Aggressiveness by lncRNA and its Mir-675 Derivative: Insight into Shared and Different Actions. Cancers (Basel). 2020; 12(7). PMC: 7407157. DOI: 10.3390/cancers12071730. View

Wu J, Li S, Jia W, Deng H, Chen K, Zhu L . Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer. PLoS One. 2015; 10(7):e0133643. PMC: 4517895. DOI: 10.1371/journal.pone.0133643. View

Gulia C, Baldassarra S, Signore F, Rigon G, Pizzuti V, Gaffi M . Role of Non-Coding RNAs in the Etiology of Bladder Cancer. Genes (Basel). 2017; 8(11). PMC: 5704252. DOI: 10.3390/genes8110339. View

Lee H, Han S, Kwon C, Lee D . Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein Cell. 2015; 7(2):100-13. PMC: 4742387. DOI: 10.1007/s13238-015-0212-y. View

Wang X, Pei X, Guo G, Qian X, Dou D, Zhang Z . Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J Cell Physiol. 2020; 235(10):6896-6904. DOI: 10.1002/jcp.29585. View

Gao H, Hao G, Sun Y, Li L, Wang Y . Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. Onco Targets Ther. 2018; 11:8001-8012. PMC: 6235328. DOI: 10.2147/OTT.S172379. View

10.

Boyerinas B, Park S, Hau A, Murmann A, Peter M . The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2009; 17(1):F19-36. DOI: 10.1677/ERC-09-0184. View

11.

Gilles M, Slack F . Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets. 2018; 22(11):929-939. PMC: 6337723. DOI: 10.1080/14728222.2018.1535594. View

12.

Matouk I, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A . The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget. 2015; 7(4):3748-65. PMC: 4826167. DOI: 10.18632/oncotarget.6387. View

13.

Chin L, Slack F . A truth serum for cancer--microRNAs have major potential as cancer biomarkers. Cell Res. 2008; 18(10):983-4. DOI: 10.1038/cr.2008.290. View

14.

Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J . H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem. 2005; 280(33):29625-36. DOI: 10.1074/jbc.M504033200. View

15.

Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P . H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015; 6(30):29209-23. PMC: 4745721. DOI: 10.18632/oncotarget.4976. View

16.

St Laurent G, Wahlestedt C, Kapranov P . The Landscape of long noncoding RNA classification. Trends Genet. 2015; 31(5):239-51. PMC: 4417002. DOI: 10.1016/j.tig.2015.03.007. View

17.

Muller V, Oliveira-Ferrer L, Steinbach B, Pantel K, Schwarzenbach H . Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. Mol Oncol. 2019; 13(5):1137-1149. PMC: 6487715. DOI: 10.1002/1878-0261.12472. View

18.

Shima H, Kida K, Adachi S, Yamada A, Sugae S, Narui K . Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness. Breast Cancer Res Treat. 2018; 170(3):507-516. DOI: 10.1007/s10549-018-4793-z. View

19.

Donati S, Ciuffi S, Brandi M . Human Circulating miRNAs Real-time qRT-PCR-based Analysis: An Overview of Endogenous Reference Genes Used for Data Normalization. Int J Mol Sci. 2019; 20(18). PMC: 6769746. DOI: 10.3390/ijms20184353. View

20.

Piergentili R, Zaami S, Cavaliere A, Signore F, Scambia G, Mattei A . Non-Coding RNAs as Prognostic Markers for Endometrial Cancer. Int J Mol Sci. 2021; 22(6). PMC: 8003471. DOI: 10.3390/ijms22063151. View